2+ day, 23+ hour ago  (186+ words) April 1 " June 30, 2026 Q2 2026 was a broad recovery led by Novo Nordisk, which reclaimed its Q1 decline. Beneath the index, Alze Cure out-licensed its Alzstatin platform to Eli Lilly and, the day after quarter-end, a second platform to Quantum Cell " marking Sweden's arrival…...

3+ day, 46+ min ago  (220+ words) Devyser Diagnostics' preliminary net sales for the second quarter of 2026 amount to SEK 60, 2 million, lower than expected. The explanation is that the company's single largest distributor built up a large inventory during 2025 and into 2026, which significantly reduced the purchasing need…...

3+ day, 22+ hour ago  (275+ words) The study enrolled 349 patients and was not stopped for safety reasons. An interim analysis simply showed that the candidate had not met the efficacy criteria required to justify continued development. MK-1167 is a modulator of the alpha-7 nicotinic receptor, a…...

4+ day, 21+ hour ago  (578+ words) " It is about finding our niche. We are trying to read the market, understand what is needed, and talk to potential partners to see whether we could fit into their operations, says Sofia Mayans, Head of Manufacturing Site at Diamyd…...

6+ day, 17+ hour ago  (538+ words) Flerie and Biosergen have adopted a merger plan under which Biosergen will be absorbed by Flerie and its operations transferred to a new subsidiary. The deal rescues a clinical-stage antifungal candidate with compelling early data from a company that ran…...

6+ day, 22+ hour ago  (430+ words) For Isofol Medical, the first half of 2026 has offered clinical data that exceeded expectations, regulatory announcements that strengthen and broaden the study program, an unexpected new therapy area and a strengthened cash flow. Bio Stock summarizes the first half of…...

1+ week, 2+ day ago  (361+ words) The US is pushing hard for Europe to pay more for pharmaceutical innovation. This week, the US Trade Representative launched a formal investigation into Germany's drug pricing, following a German bill that would save more than "16 billion in healthcare costs....

1+ week, 2+ day ago  (524+ words) The strategy shift is driven by results from the company's Phase IIa clinical trial Kandova, which shows that it is possible to identify with good precision which patients benefit most from the drug candidate rugocrixan. This insight, combined with support…...

1+ week, 3+ day ago  (330+ words) The low subscription participation does not fundamentally change the financial bottom line for the company. The structure with an issue guarantee and the parallel loan agreement with Fenja Capital of up to SEK 75 million means that Cantargia overall has access…...

1+ week, 3+ day ago  (512+ words) At the end of March, Diamyd announced that the phase III study DIAGNODE-3 " the company's confirmatory trial for retogatein in type 1 diabetes " had shown insufficient efficacy at the pre-defined interim analysis. An independent external statistical validation confirmed the futility criterion,…...